MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:42Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Guanylate cyclase C agonists]]
			[[Category:IBS treatments]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #178

2026-05-23T04:15:07Z

parser-claude batch MedTemplate pre-fill, Top 300 #178

New page

{{MedTemplate
| generic = Linaclotide
| brand = Linzess
| structure =
| classes = [[:Category:Guanylate_cyclase_C_agonists|Guanylate cyclase-C agonist]], [[:Category:IBS_treatments|IBS-C treatment]]
| uses = <vote slug="ibs-c-use">IBS with predominant constipation</vote>, <vote slug="chronic-idiopathic-constipation-use">Chronic idiopathic constipation</vote>, <vote slug="functional-constipation-pediatric-use">Functional constipation in pediatric patients 6-17 years</vote>
| starting_dose = 145 mcg PO once daily for chronic idiopathic constipation; 290 mcg daily for IBS-C; pediatric 72 mcg daily
| preparations = 72, 145, 290 mcg capsules
| fda_max = 290 mcg/d
| pill_id =
| routes = Oral
| onset = Bowel movement within 1 week; abdominal pain improvement over weeks
| duration = 24 hours
| halflife = Not meaningfully described (negligible systemic absorption — the drug acts locally and is degraded in the GI tract)<ref name="linzess-label">FDA Prescribing Information, Linzess (linaclotide), AbbVie/Ironwood, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202811s011lbl.pdf</ref>
| bioavailability = Negligible systemic absorption<ref name="linzess-label" />
| pregnancy = Limited data; minimal systemic absorption likely renders fetal risk low.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' contraindicating use in children <2 years (lethal dehydration in animal studies)<ref name="linzess-label" />
| mechanism = <vote slug="linaclotide-mech-claim">Linaclotide is a 14-amino-acid peptide agonist of guanylate cyclase-C (GC-C) on the luminal surface of intestinal epithelial cells; receptor activation raises intracellular and extracellular cGMP, which opens the CFTR chloride channel and increases chloride/bicarbonate secretion (and consequently water) into the gut lumen, accelerating transit.</vote> Extracellular cGMP separately activates submucosal sensory afferents in a way that reduces visceral pain perception, distinguishing linaclotide from purely osmotic laxatives in IBS-C. Diarrhea is the dose-limiting effect<ref name="linzess-label" />.
}}

== References ==
<references />

Linaclotide - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #178